Titleist Asset Management LLC Cuts Position in ARK Genomic Revolution ETF (BATS:ARKG)

Titleist Asset Management LLC lowered its holdings in shares of ARK Genomic Revolution ETF (BATS:ARKG) by 27.8% during the fourth quarter, HoldingsChannel.com reports. The firm owned 11,975 shares of the company’s stock after selling 4,600 shares during the period. Titleist Asset Management LLC’s holdings in ARK Genomic Revolution ETF were worth $282,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Prudential PLC raised its stake in shares of ARK Genomic Revolution ETF by 10.5% during the 4th quarter. Prudential PLC now owns 160,370 shares of the company’s stock worth $3,776,000 after buying an additional 15,200 shares during the period. Avantax Advisory Services Inc. raised its position in ARK Genomic Revolution ETF by 2.5% during the fourth quarter. Avantax Advisory Services Inc. now owns 28,701 shares of the company’s stock worth $676,000 after acquiring an additional 702 shares during the period. Raymond James Financial Inc. purchased a new position in ARK Genomic Revolution ETF during the fourth quarter valued at $2,027,000. Whipplewood Advisors LLC acquired a new stake in shares of ARK Genomic Revolution ETF in the fourth quarter valued at about $305,000. Finally, ARK Investment Management LLC increased its stake in shares of ARK Genomic Revolution ETF by 72.7% during the fourth quarter. ARK Investment Management LLC now owns 5,989 shares of the company’s stock worth $141,000 after purchasing an additional 2,521 shares in the last quarter.

ARK Genomic Revolution ETF Stock Down 18.8 %

Shares of ARK Genomic Revolution ETF stock opened at $19.18 on Tuesday. ARK Genomic Revolution ETF has a twelve month low of $17.51 and a twelve month high of $31.16. The firm’s 50-day moving average price is $24.57 and its 200 day moving average price is $24.76.

ARK Genomic Revolution ETF Profile

The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.